"ICON Public Limited Company (NASDAQ:ICLR): The stock pulled back on news that biotechnology funding has dropped, albeit from very strong growth levels. We continue to believe the company is a ...

TD Cowen adjusted its financial outlook for ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries.

Shares tumbled over 10%, leading a chip sell-off as China's new AI model prompted fresh questions on Big Tech's investments.

In a report released yesterday, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on Icon (ICLR – Research Report), with a price ...